Tags: Boehringer | Sanofi | FTC | diverstitures

FTC Requires Divestitures in $13.53 Billion Boehringer-Sanofi Deal

Image: FTC Requires Divestitures in $13.53 Billion Boehringer-Sanofi Deal

Wednesday, 28 Dec 2016 03:17 PM

The U.S. Federal Trade Commission said on Wednesday that German pharmaceutical company Boehringer Ingelheim agreed to divest five types of animal health products to settle FTC charges that a proposed asset swap with Sanofi would harm competition.

The proposed asset swap involved Boehringer Ingelheim's acquisition of Sanofi's $13.5 billion animal care subsidiary and Sanofi's obtaining the Germany company's consumer health care business unit, valued at nearly $8 billion, the FTC said.

The FTC said in a statement that without the divestitures, the proposed swap "would harm competition in the U.S. markets for various vaccines for companion animals (pets) and certain parasite control products for cattle and sheep."

© 2017 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Companies
The U.S. Federal Trade Commission said on Wednesday that German pharmaceutical company Boehringer Ingelheim agreed to divest five types of animal health products to settle FTC charges that a proposed asset swap with Sanofi would harm competition.
Boehringer, Sanofi, FTC, diverstitures
107
2016-17-28
Wednesday, 28 Dec 2016 03:17 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved